MedTrace Logo

The Efficacy of Citalopram Treatment in Acute Stroke

NCT01937182 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 642

Last updated 2017-02-24

No results posted yet for this study

Summary

We wish to conduct a prospective, randomized, double blind, placebo controlled multi center study of the combined neuroprotective and antithrombotic effects of SSRI treatment after stroke.

Hypotheses:

SSRI treatment commenced in the acute phase of stroke (day 0-7) protects against new thromboembolic events and leads to better rehabilitation. 600 stroke patients will be randomized in a 1:1 ratio.

The treatment and follow up period is 6 months. During these 6 months there will be 2 clinical follow up visits, one telephone control and one visit to evaluate compliance regarding medication.

Conditions

  • Stroke, Ischemic

Interventions

DRUG

Citalopram

Citalopram 10-40 mg per day administered orally

DRUG

Placebo

1/2-2 tablets per day with no intrinsic drug activity

Sponsors & Collaborators

  • Danish Council for Independent Research

    collaborator OTHER

  • The Danish Regions Medicine Foundation

    collaborator UNKNOWN

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Grethe Andersen, DSMc · Aarhus University Hospital

  • Kristian L Kraglund, M.D. · Aarhus University Hospital

  • Boris Modrau, M.D. · Aalborg University Hospital

  • Helle Iversen, DSMc · Glostrup University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-12-19
Completion
2016-12-19

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01937182 on ClinicalTrials.gov